Zerodha co-founder Nikhil Kamath has publicly questioned why GLP-1 weight-loss drugs have not gained more traction in India, despite strong global attention. Writing on the platform X, Kamath pointed to a gap between international enthusiasm and domestic uptake for medicines such as those in the obesity-treatment class.
GLP-1 drugs, including widely discussed products like Ozempic, have driven significant sales and investor interest in markets such as the United States. In India, however, factors including price, awareness, distribution and physician prescribing patterns can shape adoption differently than in higher-income markets.
Kamath’s remarks framed the question as a puzzle worth examining given the size of India’s population and the prevalence of metabolic conditions. His comments reflect a broader conversation among entrepreneurs and investors about why some globally successful products underperform in the Indian market.
As a prominent voice in India’s financial sector, Kamath’s observations drew engagement online, contributing to ongoing discussion about the commercial trajectory of obesity drugs in emerging markets.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.businesstoday.in/